Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2000 December;41(6) > The Journal of Cardiovascular Surgery 2000 December;41(6):931-4

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE JOURNAL OF CARDIOVASCULAR SURGERY

Rivista di Chirurgia Cardiaca, Vascolare e Toracica


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632


eTOC

 

ORIGINAL ARTICLES  THORACIC PAPERS


The Journal of Cardiovascular Surgery 2000 December;41(6):931-4

lingua: Inglese

Management of ipsilateral intrapulmonary metastases in the new TNM system for non-small cell lung cancer

Kamiyoshihara M., Kawashima O., Sakata S., Hirai T., Ishikawa S. *, Morishita Y. *

From the First Department of Surgery National Sanatorium Nishi-Gunma Hospital Shibukawa, Gunma, Japan
*Second Department of Surgery Gunma University School of Medicine Maebashi, Gunma, Japan


PDF  


Backgrounds. Recently, the Union Internationale Contre le Cancer and American Joint Committee on Cancer reclassified not only TNM staging but also ipsilateral intrapulmonary metastases (PM) as T4 in a same lobe or M1 in different lobes. To determine whether the new PM staging is appropriate, we studied the prognosis of PM.
Methods. From January 1981 to October 1997, we performed a lobectomy or pneumonectomy with mediastinal lymph node dissection, and had 42 patients with PM. We analyzed the postoperative prognosis of the patients with ipsilateral PM compared with the same stage group without PM (the non-PM).
Results. In the previous classification of PM (the old PM), 2 patients were categorized as stage IIA, 9 as IIB, 17 as IIIA, and 14 as IIIB. After reclassification (the new PM), 37 patients were categorized as stage IIIB, and 5 as IV. The old PM stage IIIA group had a significantly poor prognosis compared with the non-PM stage IIIA. However, the prognosis of the new PM group was compatible with that of the non-PM. None of the other staging group had a significant difference in the prognosis.
Conclusions. The management of PM in the new TNM system for non-small cell lung cancer is appropriate.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail